Newer methods of hormonal therapy for prostate cancer.

M. S. Soloway

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

At least 80 per cent of prostatic tumors exhibit some degree of hormone responsiveness. The preferred method of hormonal alteration has yet to be determined because new agents are currently undergoing clinical trials. The compounds tested have included cyproterone acetate, a progestational agent; flutamide, an antiandrogen that blocks the DHT-receptor complex in the tumor cell; and aminoglutethimide, which inhibits adrenal steroid production and, therefore, might further lower the level of circulating androgen following bilateral orchiectomy. The introduction of potent, synthetic analogues of gonadotropin-releasing hormone (GnRH) has provided another method of reducing the level of circulating androgen. A recent report on the efficacy of one of these analogues--leuprolide--in men with newly diagnosed metastatic prostatic cancer has revealed an initial response rate of 76 per cent (4% complete remissions, 32% partial remissions, and 40% stable) using National Prostatic Cancer Project criteria.

Original languageEnglish
Pages (from-to)30-38
Number of pages9
JournalUrology
Volume24
Issue number5 Suppl
StatePublished - Nov 1 1984

Fingerprint

Androgens
Prostatic Neoplasms
Aminoglutethimide
Leuprolide
Flutamide
Cyproterone Acetate
Androgen Antagonists
Orchiectomy
Progestins
Gonadotropin-Releasing Hormone
Neoplasms
Steroids
Clinical Trials
Hormones
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Soloway, M. S. (1984). Newer methods of hormonal therapy for prostate cancer. Urology, 24(5 Suppl), 30-38.

Newer methods of hormonal therapy for prostate cancer. / Soloway, M. S.

In: Urology, Vol. 24, No. 5 Suppl, 01.11.1984, p. 30-38.

Research output: Contribution to journalArticle

Soloway, MS 1984, 'Newer methods of hormonal therapy for prostate cancer.', Urology, vol. 24, no. 5 Suppl, pp. 30-38.
Soloway MS. Newer methods of hormonal therapy for prostate cancer. Urology. 1984 Nov 1;24(5 Suppl):30-38.
Soloway, M. S. / Newer methods of hormonal therapy for prostate cancer. In: Urology. 1984 ; Vol. 24, No. 5 Suppl. pp. 30-38.
@article{93fde982927d444a887c6ade40232ea0,
title = "Newer methods of hormonal therapy for prostate cancer.",
abstract = "At least 80 per cent of prostatic tumors exhibit some degree of hormone responsiveness. The preferred method of hormonal alteration has yet to be determined because new agents are currently undergoing clinical trials. The compounds tested have included cyproterone acetate, a progestational agent; flutamide, an antiandrogen that blocks the DHT-receptor complex in the tumor cell; and aminoglutethimide, which inhibits adrenal steroid production and, therefore, might further lower the level of circulating androgen following bilateral orchiectomy. The introduction of potent, synthetic analogues of gonadotropin-releasing hormone (GnRH) has provided another method of reducing the level of circulating androgen. A recent report on the efficacy of one of these analogues--leuprolide--in men with newly diagnosed metastatic prostatic cancer has revealed an initial response rate of 76 per cent (4{\%} complete remissions, 32{\%} partial remissions, and 40{\%} stable) using National Prostatic Cancer Project criteria.",
author = "Soloway, {M. S.}",
year = "1984",
month = "11",
day = "1",
language = "English",
volume = "24",
pages = "30--38",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5 Suppl",

}

TY - JOUR

T1 - Newer methods of hormonal therapy for prostate cancer.

AU - Soloway, M. S.

PY - 1984/11/1

Y1 - 1984/11/1

N2 - At least 80 per cent of prostatic tumors exhibit some degree of hormone responsiveness. The preferred method of hormonal alteration has yet to be determined because new agents are currently undergoing clinical trials. The compounds tested have included cyproterone acetate, a progestational agent; flutamide, an antiandrogen that blocks the DHT-receptor complex in the tumor cell; and aminoglutethimide, which inhibits adrenal steroid production and, therefore, might further lower the level of circulating androgen following bilateral orchiectomy. The introduction of potent, synthetic analogues of gonadotropin-releasing hormone (GnRH) has provided another method of reducing the level of circulating androgen. A recent report on the efficacy of one of these analogues--leuprolide--in men with newly diagnosed metastatic prostatic cancer has revealed an initial response rate of 76 per cent (4% complete remissions, 32% partial remissions, and 40% stable) using National Prostatic Cancer Project criteria.

AB - At least 80 per cent of prostatic tumors exhibit some degree of hormone responsiveness. The preferred method of hormonal alteration has yet to be determined because new agents are currently undergoing clinical trials. The compounds tested have included cyproterone acetate, a progestational agent; flutamide, an antiandrogen that blocks the DHT-receptor complex in the tumor cell; and aminoglutethimide, which inhibits adrenal steroid production and, therefore, might further lower the level of circulating androgen following bilateral orchiectomy. The introduction of potent, synthetic analogues of gonadotropin-releasing hormone (GnRH) has provided another method of reducing the level of circulating androgen. A recent report on the efficacy of one of these analogues--leuprolide--in men with newly diagnosed metastatic prostatic cancer has revealed an initial response rate of 76 per cent (4% complete remissions, 32% partial remissions, and 40% stable) using National Prostatic Cancer Project criteria.

UR - http://www.scopus.com/inward/record.url?scp=0021519009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021519009&partnerID=8YFLogxK

M3 - Article

C2 - 6437034

AN - SCOPUS:0021519009

VL - 24

SP - 30

EP - 38

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5 Suppl

ER -